Energenesis Biomedical Co (TPE:6657) PEG Ratio: N/A (As of Jul. 11, 2026)


TPE:6657 Energenesis Biomedical Co Ltd TPE:6657
64 GF Score
Price NT$35.30
GF Value NT$51.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Energenesis Biomedical Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Energenesis Biomedical Co's PE Ratio without NRI is 0.00. Energenesis Biomedical Co's 5-Year EBITDA growth rate is -10.10%. Therefore, Energenesis Biomedical Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Energenesis Biomedical Co's PEG Ratio or its related term are showing as below:



TPE:6657's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.915
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Energenesis Biomedical Co  (TPE:6657) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Energenesis Biomedical Co PEG Ratio Related Terms


Energenesis Biomedical Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Energenesis Biomedical Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Energenesis Biomedical Co PEG Ratio Chart

Energenesis Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Energenesis Biomedical Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TPE:6657 vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, Energenesis Biomedical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Energenesis Biomedical Co PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Energenesis Biomedical Co's PEG Ratio falls into.


TPE:6657
64GF Score
Energenesis Biomedical Co Ltd TPE:6657
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Energenesis Biomedical Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Energenesis Biomedical Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-10.10
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?

Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued. The current stock price of NT$35.30 is trading 31.3% below its estimated GF Value™ of NT$51.40. GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.

Key valuation signals for TPE:6657:

  • PEG Ratio: N/A
  • GF Value™: NT$51.40 vs. price of NT$35.30 (31.3% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Energenesis Biomedical Co Business Description

Address No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score

Get the complete analysis for TPE:6657

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.30
Price
NT$51.40
GF Value